medical specialists |
||||||
|
News for 31-Jan-26 Source: MedicineNet Prevention and Wellness General Source: MedicineNet Prevention and Wellness General Source: MedicineNet Senior Health General Source: MedicineNet Senior Health General
|
The Best medical specialists websiteAll the medical specialists information you need to know about is right
here. Presented and researched by http://www.md-news.net. We've searched
the information super highway far and wide to provide you with the
best medical specialists site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
medical specialists
The medical specialists links on the right side of this page will take you directly to the specific item you need so look around. We have made it easy for you and of course this company stands behind their medical specialists with total satisfaction guarantees Somewhere on this page you will find the exact medical specialists link you are looking for as we have done extensive research to put the best sources available at your fingertips. Just take a few minutes and you will find exactly the medical specialists information you need. medical specialists
When you're seeking information about medical specialists the results can seem extremely overwhelming. But relax, because we've sifted through all the medical specialists web sites we could find and have discovered the finest ones that will produce the results you want, and how you want them. We know how crucial good results are when you're searching for medical specialists. Some Internet sites are superior than others and will meet your medical specialists requirements in a better fashion. If you're looking for a high standard medical specialists site you know you can count on, we suggest the above web site. We have taken the tiresome task out of your medical specialists shopping and reduced our list of medical specialists web sites down to only finest around. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| MD Newscast Medical Newscast Net Meetings |